Autoimmune Hemolytic Anemia Medical Services in China

Autoimmune Hemolytic Anemia (AIHA) is a rare, heterogeneous hematologic disorder characterized by the immune-mediated destruction of autologous red blood cells (RBCs), leading to hemolysis and consequent anemia. It arises when the body’s immune system mistakenly produces autoantibodies—most commonly IgG (warm AIHA) or IgM (cold agglutinin disease)—that bind to RBC surface antigens, triggering complement activation and/or macrophage-mediated phagocytosis in the spleen or liver. Less common subtypes include mixed-type and drug-induced AIHA. Pathogenesis involves loss of B-cell tolerance, dysregulated T-follicular helper cell activity, impaired regulatory T-cell function, and genetic predispositions (e.g., polymorphisms in FCGR genes or HLA-DRB1*03/04). Secondary AIHA may accompany lymphoproliferative disorders (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma), systemic autoimmune diseases (e.g., SLE, rheumatoid arthritis), infections (e.g., Mycoplasma pneumoniae, EBV, HIV), or immunomodulatory therapies. Epidemiologically, AIHA affects approximately 1–3 per 100,000 individuals annually, with bimodal peaks in childhood (often post-infectious) and older adulthood (median age 50–70 years). Females are affected slightly more often than males (F:M ≈ 1.3:1). Risk factors include underlying autoimmune or hematologic malignancies, prior splenectomy, certain medications (e.g., fludarabine, alpha-methyldopa), and genetic susceptibility. Untreated or refractory AIHA can cause profound fatigue, dyspnea, pallor, jaundice, dark urine, tachycardia, and—in severe cases—high-output heart failure, renal injury from hemoglobinuria, or thromboembolic complications due to chronic inflammation and hypercoagulability. Quality of life is significantly impaired: patients report persistent fatigue, reduced physical stamina, anxiety about hemolytic crises, treatment-related side effects (e.g., steroid-induced insomnia, weight gain, osteoporosis), and social withdrawal due to unpredictable symptom flares. Long-term management requires vigilant monitoring for relapse, secondary malignancy, and iatrogenic complications—especially in elderly patients on prolonged immunosuppression. Psychosocial support, patient education on infection prevention, and individualized treatment escalation strategies are integral to holistic care.

Autoimmune Hemolytic Anemia (AIHA) is a heterogeneous group of disorders characterized by premature destruction of red blood cells (RBCs) due to autoantibodies directed against erythrocyte antigens. Classified primarily as warm antibody AIHA (IgG-mediated, optimal at 37°C), cold agglutinin disease (IgM-mediated, optimal at 0–4°C), and mixed or atypical forms, AIHA requires prompt diagnosis and risk-stratified management. Treatment goals include halting hemolysis, correcting anemia, preventing complications (e.g., thromboembolism, renal injury, heart failure), and addressing underlying triggers—such as lymphoproliferative disorders, autoimmune diseases (e.g., SLE), infections (e.g., Mycoplasma pneumoniae, EBV), or drug exposure.

Conservative treatment serves as the cornerstone for mild-to-moderate cases and supportive care across all severities. Patients with hemoglobin >10 g/dL and stable clinical status may require only close observation, serial CBCs, reticulocyte counts, LDH, haptoglobin, and indirect bilirubin monitoring every 3–7 days initially. Avoidance of known precipitants is critical: patients with cold agglutinin disease must minimize cold exposure (e.g., wearing gloves, avoiding refrigerated environments); those with drug-induced AIHA discontinue the offending agent immediately. Transfusion support is indicated selectively—only when symptomatic anemia (e.g., dyspnea, angina, tachycardia, fatigue) or hemodynamic instability exists—and must be performed cautiously using warmed, leukoreduced RBC units. Crossmatching may be challenging due to pan-agglutination; phenotypically matched units (e.g., Rh- and Kell-negative) are preferred when feasible. Iron, folate, and vitamin B12 supplementation are recommended during active hemolysis to support compensatory erythropoiesis, particularly given increased RBC turnover.

First-line pharmacotherapy for warm AIHA is corticosteroids—typically oral prednisone 1.0–1.5 mg/kg/day (max 80 mg/day) for 1–3 weeks, followed by a slow taper over 3–6 months. Approximately 70–80% of patients respond within 2–3 weeks; however, relapse occurs in up to 50% upon discontinuation. For steroid-refractory, dependent, or relapsed cases, second-line agents include rituximab (375 mg/m² weekly × 4 doses), which achieves response rates of 60–80% and durable remission in ~40% at 2 years. Other immunosuppressants include mycophenolate mofetil (1000–1500 mg twice daily), azathioprine (2–3 mg/kg/day), cyclosporine (3–5 mg/kg/day), and newer agents such as fostamatinib (a SYK inhibitor approved in some jurisdictions for chronic immune thrombocytopenia, under investigation in AIHA). In cold agglutinin disease, rituximab monotherapy yields ~50% response; combination with bendamustine significantly improves depth and duration of response. Complement inhibitors—including sutimlimab (anti-C1s monoclonal antibody, FDA-approved for CAD) and ravulizumab (anti-C5)—are transformative for severe CAD, rapidly normalizing hemolysis markers and transfusion independence in >80% of treated patients. Intravenous immunoglobulin (IVIG) has limited utility in warm AIHA (short-lived effect, high cost) and is generally reserved for acute, life-threatening hemolysis pre-surgery or in pregnancy.

Surgical intervention is rarely indicated but remains pivotal in select scenarios. Splenectomy is considered third-line therapy for warm AIHA refractory to steroids and rituximab. The spleen is the primary site of IgG-opsonized RBC sequestration and destruction; removal confers durable remission in ~60% of responders, with median response duration exceeding 5 years. Preoperative vaccination (against Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis) and lifelong penicillin prophylaxis (especially in children and high-risk adults) are mandatory to mitigate overwhelming post-splenectomy infection (OPSI). Laparoscopic splenectomy is preferred for its reduced morbidity, shorter hospital stay (typically 2–3 days), and faster recovery. In rare cases of AIHA secondary to localized lymphoid malignancy (e.g., splenic marginal zone lymphoma), resection may be both diagnostic and therapeutic. Surgical management plays no role in primary cold agglutinin disease, as hemolysis occurs predominantly intravascularly via complement activation.

Treatment advantages in China reflect rapid integration of global evidence with robust domestic infrastructure. Major tertiary hospitals—such as Peking University People’s Hospital, Shanghai Ruijin Hospital, and West China Hospital—host specialized hematology centers with multidisciplinary AIHA task forces (hematologists, transfusion medicine specialists, clinical immunologists, and molecular pathologists). Access to rituximab and newer biologics is increasingly widespread through national health insurance reimbursement (e.g., rituximab covered since 2020 for refractory AIHA; sutimlimab undergoing Phase III trials in China). Domestic biosimilars (e.g., rituximab biosimilars approved by NMPA) reduce costs by >40% versus originators without compromising efficacy or safety. Advanced diagnostics—including flow cytometry for autoantibody characterization, next-generation sequencing for clonal lymphoid disorders, and complement functional assays—are routinely available in top-tier centers. Moreover, China’s large patient volume enables rapid enrollment in investigator-initiated trials (IITs) evaluating novel agents like efgartigimod (FcRn antagonist) and belumosudil (ROCK2 inhibitor), positioning Chinese centers at the forefront of AIHA therapeutics innovation.

Recovery advice emphasizes long-term vigilance and patient empowerment. Patients should monitor for signs of relapse (fatigue, pallor, jaundice, dark urine, palpitations) and seek immediate evaluation if hemoglobin drops >2 g/dL over 1 week or new symptoms emerge. Routine follow-up includes CBC and reticulocyte count every 1–3 months during remission, annual LDH/haptoglobin, and periodic screening for underlying lymphoproliferative disease (e.g., peripheral blood flow cytometry, CT imaging if clinically indicated). Lifestyle modifications include strict sun protection (for photosensitive patients on immunosuppressants), influenza/pneumococcal vaccination annually, avoidance of live vaccines during active immunosuppression, and cautious use of NSAIDs or anticoagulants due to bleeding/thrombosis risks. Psychosocial support is integral: AIHA’s chronic, relapsing nature contributes to anxiety and depression; referral to hematologic social workers or cognitive behavioral therapy programs is encouraged. Finally, patients should maintain a treatment diary documenting medications, side effects (e.g., hyperglycemia, insomnia, weight gain with steroids), transfusion history, and laboratory trends—facilitating shared decision-making and timely intervention. With contemporary, individualized management, most patients achieve sustained remission and near-normal life expectancy.